Masaru Muraoka

发表

Hepatitis B virus (HBV)‐infected patients with low hepatitis B surface antigen and high hepatitis B core‐related antigen titers have a high risk of HBV‐related hepatocellular carcinoma

N. Enomoto, M. Sakamoto, K. Moriishi, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus

N. Enomoto, M. Sakamoto, K. Moriishi, 2015, Journal of Virology.

Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy

N. Enomoto, K. Yamauchi, S. Maekawa, 2021, Hepatology communications.

N. Enomoto, M. Matsuda, K. Moriishi, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.

M. Kurosaki, N. Izumi, T. Nishimura, 2013, World journal of gastroenterology.

α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C

N. Enomoto, M. Kurosaki, S. Kakinuma, 2013, Hepatology.

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

N. Enomoto, M. Kurosaki, N. Sakamoto, 2012, Hepatology.

HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers

N. Enomoto, M. Sakamoto, K. Moriishi, 2019, PloS one.

Genetic alterations related to endoscopic treatment of colorectal tumors

N. Enomoto, K. Mochizuki, S. Maekawa, 2019, JGH open : an open access journal of gastroenterology and hepatology.

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma

N. Enomoto, S. Maekawa, M. Fukasawa, 2021, Reports.

Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C

N. Enomoto, M. Sakamoto, M. Nakagawa, 2018, Journal of Gastroenterology.

Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C

N. Enomoto, M. Kurosaki, S. Kakinuma, 2014, Journal of Gastroenterology.

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

N. Enomoto, M. Kurosaki, N. Izumi, 2013, Cancer.

Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma

N. Enomoto, M. Sakamoto, S. Maekawa, 2015, Mediators of inflammation.

Role of magnifying endoscopy with narrow‐band imaging in the diagnosis of noninvasive gastric neoplasia

N. Enomoto, K. Mochizuki, Yukiko Asakawa, 2021, JGH open : an open access journal of gastroenterology and hepatology.

Deep sequencing analysis of serum hepatitis B virus‐RNA during nucleot(s)ide analogue therapy

N. Enomoto, K. Moriishi, S. Maekawa, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Prospective comparison of real‐time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients

M. Kurosaki, N. Izumi, T. Nishimura, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma

N. Enomoto, S. Maekawa, M. Fukasawa, 2022, Oncology.

Spontaneous portosystemic shunt diameter predicts liver function after balloon‐occluded retrograde transvenous obliteration

N. Enomoto, H. Onishi, S. Maekawa, 2022, JGH Open.

HBV patients with low HBsAg and high HBcrAg titers have a high risk of HBV‐related HCC

N. Enomoto, M. Sakamoto, K. Moriishi, 2018 .

Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography

M. Yin, U. Motosugi, N. Enomoto, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients

M. Kurosaki, N. Izumi, Y. Asahina, 2014, Journal of Gastroenterology.

The Impact of Antiviral Therapy for Hepatitis C Virus on the Survival of Patients after Hepatocellular Carcinoma Treatment

N. Enomoto, S. Maekawa, Y. Nakayama, 2022, Internal medicine.

Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study

N. Enomoto, M. Kurosaki, N. Izumi, 2014, Oncology.

Analysis of direct‐acting antiviral‐resistant hepatitis C virus haplotype diversity by single‐molecule and long‐read sequencing

N. Enomoto, K. Yamauchi, S. Maekawa, 2022, Hepatology communications.

Comprehensive genetic analysis of cholangiolocellular carcinoma with a coexistent hepatocellular carcinoma‐like area and metachronous hepatocellular carcinoma

N. Enomoto, S. Kakinuma, M. Nakagawa, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease

H. Morisaka, N. Enomoto, H. Onishi, 2023, Journal of gastroenterology and hepatology.

Hepatic Amyloidosis with an Extremely High Stiffness Value on Magnetic Resonance Elastography

U. Motosugi, N. Enomoto, M. Sakamoto, 2016, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

Assessment of lower limb muscle strength can predict fall risk in patients with chronic liver disease

S. Maekawa, Mitsuaki Sato, S. Takano, 2024, Scientific reports.

Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma

S. Maekawa, Mitsuaki Sato, S. Takano, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma

N. Enomoto, S. Maekawa, Mitsuaki Sato, 2023, Oncology.